Truven Health Analytics, DOAC Market Data Report. Truven Bleeding Events Report: Commercial, Medicare, & Medicaid Populations. Boston, MA: Alexion Pharmaceuticals, Inc. ANDEXXA ® (coagulation factor Xa (recombinant), inactivated-zhzo). ‡ RASUNOA study design: Based on a prospective, multicenter, observational substudy of patients with nontraumatic DOAC-related intracerebral hemorrhage (n=45). † ARISTOTLE study design: Based on a double-blind, double-dummy, randomized clinical trial comparing apixaban with warfarin in patients with AF (N=18,201). * ROCKET AF study design: Based on a multinational, randomized, double-blind, double-dummy clinical trial comparing rivaroxaban with warfarin in patients with atrial fibrillation (AF) (N=14,264). Gastrointestinal bleeds account for 39%-56% of all bleeding events in rivaroxaban- and apixaban-treated patients 9,10.In a prospective, multicenter, observational study, substantial hematoma expansion (defined as a volume increase of ≥33% or ≥6 mL) occurred in approximately, 40% of intracerebral hemorrhage patients taking DOACs 8‡.In nonvalvular atrial fibrillation clinical trials, 48% of rivaroxaban-treated patients (ROCKET AF Trial*) and 45% of apixaban-treated patients (ARISTOTLE Trial †) with intracranial hemorrhage died within 30 days 6,7.Here are some facts about these patients:
0 kommentar(er)
